Eupraxia Pharmaceuticals (NASDAQ:EPRX) Given New $16.00 Price Target at HC Wainwright

Posted by Geri Gentry on Nov 12th, 2026

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Free Report) had its price objective boosted by HC Wainwright from $11.00 to $16.00 in a report issued on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other research firms have also commented on EPRX. Wall Street Zen lowered Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Sunday. Oppenheimer reiterated an “outperform” rating on shares of Eupraxia Pharmaceuticals in a research report on Tuesday, October 20th. Royal Bank Of Canada initiated coverage on Eupraxia Pharmaceuticals in a report on Monday. They set an “outperform” rating and a $14.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 15th. Finally, Stifel Nicolaus set a $25.00 price target on Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Eupraxia Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

View Our Latest Stock Analysis on EPRX

Eupraxia Pharmaceuticals Stock Performance

Shares of NASDAQ:EPRX opened at $8.06 on Wednesday. The company’s 50 day moving average price is $7.62 and its two-hundred day moving average price is $7.25. Eupraxia Pharmaceuticals has a 12-month low of $5.63 and a 12-month high of $9.32. The firm has a market cap of $541.97 million, a PE ratio of -7.60 and a beta of 1.04. The company has a quick ratio of 16.00, a current ratio of 16.00 and a debt-to-equity ratio of 0.02.

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.03. Equities research analysts predict that Eupraxia Pharmaceuticals will post -0.90 earnings per share for the current year.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. increased its holdings in shares of Eupraxia Pharmaceuticals by 28.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company’s stock worth $133,000 after buying an additional 3,500 shares in the last quarter. AXQ Capital LP increased its holdings in Eupraxia Pharmaceuticals by 34.2% in the 2nd quarter. AXQ Capital LP now owns 21,150 shares of the company’s stock worth $140,000 after purchasing an additional 5,390 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in Eupraxia Pharmaceuticals in the 2nd quarter worth about $4,037,289. Bank of America Corp DE bought a new position in Eupraxia Pharmaceuticals in the second quarter valued at about $1,750,000. Finally, Jupiter Topco LLC bought a new position in Eupraxia Pharmaceuticals in the second quarter valued at about $6,851,000.

Key Eupraxia Pharmaceuticals News

Investors following EPRX have been watching these news items:

Positive Sentiment: HC Wainwright raised its price target to $16 from $11 and reiterated a “buy” rating. The higher target signals greater analyst optimism about EPRX’s prospects. HC Wainwright rating information
Neutral Sentiment: RBC Capital issued a new rating on EPRX, but the available report does not specify the rating or its rationale. RBC Capital rating report
Negative Sentiment: The company established a $125 million at-the-market (ATM) offering program. Selling shares under the program could raise funds but may dilute existing shareholders; the announcement does not mean the full amount has been raised. ATM offering announcement

About Eupraxia Pharmaceuticals

(Get Free Report)

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing treatments that use its DiffuSphere drug-delivery technology. The polymer-based platform is designed to release medicines over an extended period and deliver them locally to targeted tissues. The company’s lead candidate, EP-104IAR, is an extended-release formulation of fluticasone propionate being developed as an injection into the knee for people with osteoarthritis. Eupraxia is also exploring applications of its delivery platform in other conditions, including eosinophilic esophagitis.